Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Fuji
Johnson and Johnson
US Army
Healthtrust
Accenture
Cerilliant
QuintilesIMS
Julphar
Deloitte

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,580,830

« Back to Dashboard

Which drugs does patent 8,580,830 protect, and when does it expire?


Patent 8,580,830 protects ZUPLENZ and is included in one NDA.

This patent has fourteen patent family members in ten countries.

Summary for Patent: 8,580,830

Title:Non-mucoadhesive film dosage forms
Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.
Inventor(s): Leichs; Christian (Alfdorf, DE), Breitenbach; Armin (Leverkusen, DE), Lehrke; Ingo (Cologne, DE), Galfetti; Paolo (Comasco, IT)
Assignee: Labtec GmbH (DE) APR Applied Pharma Research S.A. (CH)
Application Number:12/443,414
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Midatech Pharma Us
ZUPLENZ
ondansetron
FILM;ORAL022524-001Jul 2, 2010RXYesNo► Subscribe► SubscribeY
Midatech Pharma Us
ZUPLENZ
ondansetron
FILM;ORAL022524-002Jul 2, 2010RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,580,830

PCT Information
PCT FiledOctober 02, 2007PCT Application Number:PCT/EP2007/008579
PCT Publication Date:April 10, 2008PCT Publication Number: WO2008/040534

Non-Orange Book Patents for Patent: 8,580,830

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,682,037Non-mucoadhesive film dosage forms► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,580,830

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand575900► Subscribe
Mexico2009003372► Subscribe
South Korea101448050► Subscribe
South Korea20090080037► Subscribe
European Patent Office2444072► Subscribe
European Patent Office2248519► Subscribe
European Patent Office2076251► Subscribe
Germany202007019476► Subscribe
China105168186► Subscribe
China101626756► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Chinese Patent Office
Dow
Julphar
Cantor Fitzgerald
US Army
Merck
Boehringer Ingelheim
Cerilliant
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot